A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma

drug protocol number
CQAW039A2316
drug sponsor
Novartis
drug study
QAW039/Fevipiprant
drug trial site
KFMC
drug status
Completed
drug phase